| 引用本文: |
殷潇,方欣,胡江蔺,等.舒尼替尼治疗转移性肾细胞癌的预算影响分析[J].中国卫生经济,2016,(12):67-69.[点击复制] |
.Budget Impact Analysis on Using Sunitinib for Metastatic Renal Carcinoma[J].CHINESE HEALTH ECONOMICS,2016,(12):67-69.[点击复制] |
|
| 摘要: |
| 目的：通过对舒尼替尼进行预算影响分析，为药品报销目录的遴选决策制定提供科学依据。方法: 构建预算影响分析模型，测算舒尼替尼在进入医保目录之后对医保支出的预期影响。结果: 如果2015年舒尼替尼进入城镇医保目录，2015到2019年mRCC患者医保预算总费用的增幅分别为18.5%、23.1%、27.8%、32.4% 和37.0%。结论: 将舒尼替尼纳入城镇医保增加医保预算费用，增幅和各变量呈线性相关。 |
| 关键词: |
| DOI： |
|
| 基金项目: |
|
| Budget Impact Analysis on Using Sunitinib for Metastatic Renal Carcinoma |
|
| () |
| Abstract: |
| Objective: To conduct a budget impact analysis on Sunitinib, provide references for its reimbursement policy on Urban Medical Insurance Plan. Methods: Budget impact analysis model was constructed to measure the expected changes in the expenditure of medical insurance system. Results: If Sunitinib could be reimbursed since 2015, the increase rate of medical insurance budget on mRR patient in 2015-2019 will be 18.5%, 23.1%, 27.8%, 32.4% and 37.0%. Conclusion: Reimbursement of Sunitinib will increase the total budget of medical insurance, and linear correlation was found between increase rate and variables. |
| Key words: |
